If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Concomitant Use With an Insulin Secretagogue or With Insulin
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
insulin secretagogues, such as sulfonylureas, or
Enclosed Prescribing Information
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Date of Last Review: July 10, 2018